Danial C, Lingala B, Balise R, Oro AE, Reddy S, Colevas A, Chang ALS. Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma.
Br J Dermatol 2013;
169:673-6. [PMID:
23521172 PMCID:
PMC4006071 DOI:
10.1111/bjd.12333]
[Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/16/2013] [Indexed: 11/28/2022]
Abstract
BACKGROUND
Metastatic basal cell carcinoma (BCC) is a rare but life-threatening condition. Prior estimates of overall survival (OS) from time of diagnosis of distant metastasis to death are approximately 8-14 months. However, these estimates are based on analyses of case reports published prior to 1984.
OBJECTIVES
To assess an updated OS in patients with metastatic BCC at a single academic institution.
METHODS
Using patients seen from 1997 to 2011, a retrospective chart review was performed on biopsy-confirmed cases of distant metastatic BCC at Stanford University School of Medicine. Kaplan-Meier analysis was used to determine OS and progression-free survival (PFS).
RESULTS
Ten consecutive cases of distant metastatic BCC were identified. Median OS was 7·3 years [95% confidence interval (CI) 1·6-∞]; median PFS was 3·4 years (95% CI 1·1-5·2).
CONCLUSIONS
Our findings suggest that OS in patients with distant metastatic BCC may be more favourable than previously reported.
Collapse